Endocrine Abstracts

Introduction: Data concerning patients with adrenal insufficiency (AI) have been limited by small numbers of patients reflecting the relatively low prevalence of this disease. The European Adrenal Insufficiency Registry (EU-AIR) is a multicenter observational study of patients with both primary and secondary AI. Enrollment commenced August 2012. Comprehensive demographic data, aetiology of AI, and details of glucocorticoid replacement therapy are collected at baseline. Safety data and treatment information are collected prospectively at subsequent clinic visits. Patient diaries are used to record intercurrent illnesses and illness-related dose changes between visits. Here we present the baseline data of enrolled patients up to December 2013.

Results: 671 patients were registered in EU-AIR at time of analysis (239 primary AI, 389 secondary AI and 43 CAH). Patients were of mean age 52.6±16.9 years, 55.9% female’s. There was no difference in age between primary or secondary AI patients, however, the primary AI cohort showed a greater proportion of females (70 vs 48%). Mean daily hydrocortisone dose equivalents were 13.0±5.5 and 9.9±3.3 mg/m² BSA for primary and secondary AI respectively. BMI of primary AI males and females was 26.4±4.6 and 26.1±5.0 kg/m², and for secondary AI 29.3±5.0 and 29.1±6.9 kg/m² respectively. Waist circumference of primary AI males and females was 93.7±18.3 and 88.3±14.5 cm, and for secondary AI 102.5±12.5 and 93.1±14.9 cm respectively.

Of the overall cohort maintained on conventional glucocorticoid replacement baseline metabolic indices showed: total cholesterol 5.5±1.3 mmol/l; LDL-C 3.4±2.6 mmol/l; HDL-C 1.6±0.6 mmol/l; ApoB/ApoA1 0.657±0.267; HbA1c 5.8±1.7%; and fasting glucose 6.1±9.9 mmol/l.

Conclusions: Prospective observational data of a large cohort of patients with AI is likely to impart significant revelations regarding the impact of this disease on individuals, long-term outcomes, subgroups of patients at particular risk, and potentially allow comparison of alternate glucocorticoid regimens.